RAF1 and hereditary clear cell renal cell carcinoma: Sorafenib (SFN) (BAY 43-9006; Nexavar), which potently inhibits both the c-Raf (Raf-1) and b-Raf isoforms, was approved by the FDA in 2005 for treatment of advanced renal cell carcinoma [11].